NFL:
League denies misuse of painkillers described in court filings
Send a link to a friend
[March 10, 2017]
(Reuters) - NFL teams violated
federal laws governing prescription drugs, according to a Washington
Post story based on sealed court documents contained in a federal
lawsuit filed by former players against the league and reviewed by
the newspaper.
The documents showed that the league disregarded guidance from the
Drug Enforcement Administration (DEA) on how to store, track,
transport and distribute controlled substances, the Post said.
The National Football League denied the allegations made in the
lawsuit which was brought against the league by a group of retired
players.
"The allegations made by plaintiffs are meritless and the league and
its clubs will continue vigorously to defend these claims," NFL
spokesman Brian McCarthy told Reuters on Thursday in an e-mail when
asked for comment.
"The NFL clubs and their medical staffs are all in compliance with
the Controlled Substances Act."
"The NFL clubs and their medical staffs continue to put the health
and safety of our players first, providing all NFL players with the
highest quality medical care. Any claim or suggestion to the
contrary is simply wrong."
[to top of second column] |
![](http://archives.lincolndailynews.com/2017/Mar/10/images/ads/current/ccaonline_lda050208.png)
The sealed court filing, which includes testimony and
documents by team and league medical personnel, describes multiple
instances in which team and league officials were made aware of DEA
guidelines and were either slow in responding or failed to comply,
the Post said.
The suit also contained data showing widescale use by medical staff
at teams of painkillers and anti-inflammatories, the newspaper said.
![](http://archives.lincolndailynews.com/2017/Mar/10/images/ads/current/charrons_bch041713.png)
Reuters was unable to independently verify the allegations in the
suit.
(Reporting by Larry Fine in New York; Editing by Alison Williams) [© 2017 Thomson Reuters. All
rights reserved.]
Copyright 2017 Reuters. All rights
reserved. This material may not be published, broadcast, rewritten
or redistributed. |